Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Was it simply a fluke that he kept treating strikingly young patients? Or was his practice one tiny data point in a larger trend? He found his answer after sifting through national health data: ...

After battling ovarian cancer, Jennifer Garam found meaning in encouraging those facing serious illnesses to advocate for ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

UVA Health's Melanie Rutkowski, PhD, and her team are expanding our understanding of the microbiome and how it influences diseases such as breast and ovarian cancer.

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today ...

UVA Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.